TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects

Abstract: Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) agonists induce tumor-specific apoptosis indicating that they may be an attractive therapeutic strategy against cancers, including multiple myeloma (MM). Osteoclastogenesis is highly induced in MM, which in turn enhances MM gr...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Hirofumi Tenshin, Jumpei Teramachi, Asuka Oda, Ryota Amachi, Masahiro Hiasa, Ariunzaya Bat-Erdene, Keiichiro Watanabe, Masami Iwasa, Takeshi Harada, Shiro Fujii, Kumiko Kagawa, Kimiko Sogabe, Shingen Nakamura, Hirokazu Miki, Kiyoe Kurahashi, Sumiko Yoshida, Kenichi Aihara, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto, Masahiro Abe
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2017-11-01
Colecção:	Blood Advances
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2473952920301269
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!